Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1
Teplizumab may preserve β-cell function in APS-1-associated T1D. Larger studies are needed to define efficacy, durability, and immunologic and tissue mechanisms in this rare context.
Authors
- William E. Russell (ORCID: https://orcid.org/0000-0001-7609-0434)
- Alexander Falk (ORCID: https://orcid.org/0000-0003-2106-9413)
- Jordan M. Ross (ORCID: https://orcid.org/0000-0003-4345-0135)
- John Virostko (ORCID: https://orcid.org/0000-0003-3413-8801)
- Jonathan M. Williams (ORCID: https://orcid.org/0000-0001-8973-2950)
- Michail S. Lionakis (ORCID: https://orcid.org/0000-0003-4994-9500)
- Joseph Pechacek
- Alicia Diaz-Thomas (ORCID: https://orcid.org/0000-0002-0168-6855)
- Lauren M. LeStourgeon (ORCID: https://orcid.org/0000-0002-8265-6892)
- Daniel J. Moore (ORCID: https://orcid.org/0000-0002-6889-9345)
- Michael J. Haller (ORCID: https://orcid.org/0000-0002-2803-1824)
- Justin M. Gregory (ORCID: https://orcid.org/0000-0003-2700-0062)
- Melissa A. Hilmes (ORCID: https://orcid.org/0000-0002-3662-6692)
- Taura Webb
- Christopher Wilson (ORCID: https://orcid.org/0000-0002-7562-8420)
- Martina Drawdy
Institutions
- University of Tennessee Health Science Center (US)
- Vanderbilt University (US)
- University of Florida Health (US)
- University of Florida (US)
- Pensacola Historical Society (US)
- National Institute of Allergy and Infectious Diseases (US)
- University of West Florida (US)
- The University of Texas at Austin (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-11-12
- DOI
- https://doi.org/10.2337/dc25-1444
- Citations
- 1
- Primary Topic
- Adrenal Hormones and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.29